US regulators have approved a label update to Bristol-Myers Squibb’s Opdivo, waving through a new dosing option for the immunotherapy of every four weeks. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/bms_opdivo_cleared_for_monthly_use_1226100GlaxoSmithKline has announced that Emma Walmsley will take over from current chief executive Andrew Witty following his retirement at the end of March next year. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/gsk_names_new_chief_executive_1137962Sanofi Pasteur and MSD have announced the end of their European vaccines joint venture so that their own “distinct growth strategies” can be pursued instead. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sanofi,_msd_to_dismantle_vaccines_jv_1020306Breztri Aerosphere is also under regulatory review in the EU - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_copd_therapy_wins_us_approval_1345436The closing of the acquisition remains subject to other customary closing conditions - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/us_regulators_permit_abbvieallergan_merger_1339868Teva Pharmaceutical Industries is planning to sell off assets and operations of Actavis Generics in the UK and Ireland to Intas Pharmaceuticals subsidiary Accord Healthcare for £603 million. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/teva_divests_uk,_ireland_assets_1154632Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire_turns_down_takedas_advances_1232652AstraZeneca has completed its deal to sublicense certain rights to Movantik to RedHill Biopharma - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_licences_movantik_rights_to_redhill_1334146Shire's proposal to acquire Baxalta for around $32 billion and create "the global leader in rare diseases" has now been approved by both sets of shareholders. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shareholders_approve_$32bn_shirebaxalta_marriage_1032351Around half of England’s population is now served by an ICS - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nhs_england_confirms_four_new_icss_1340155
